284 related articles for article (PubMed ID: 24102360)
1. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
2. Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients.
Zhang J; Zhou W
Food Chem Toxicol; 2012 Jul; 50(7):2289-93. PubMed ID: 22525860
[TBL] [Abstract][Full Text] [Related]
3. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
[TBL] [Abstract][Full Text] [Related]
4. [Magnesium premedication prevents Cisplatin-induced nephrotoxicity in patients with esophageal and hypopharyngeal cancer].
Hirai S; Kaida S; Ito T; Hasebe S; Ueno M; Udagawa H; Hayashi M
Gan To Kagaku Ryoho; 2013 Jun; 40(6):743-7. PubMed ID: 23863650
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.
Tzvetkov MV; Behrens G; O'Brien VP; Hohloch K; Brockmöller J; Benöhr P
Pharmacogenomics; 2011 Oct; 12(10):1417-27. PubMed ID: 21902499
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.
Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant C; Bowles DW; George B; Wen X; Aleksunes LM; Joy MS
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640195
[TBL] [Abstract][Full Text] [Related]
8. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.
Lanvers-Kaminsky C; Sprowl JA; Malath I; Deuster D; Eveslage M; Schlatter E; Mathijssen RH; Boos J; Jürgens H; Am Zehnhoff-Dinnesen AG; Sparreboom A; Ciarimboli G
Pharmacogenomics; 2015; 16(4):323-32. PubMed ID: 25823781
[TBL] [Abstract][Full Text] [Related]
9. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of
Zazuli Z; Otten LS; Drögemöller BI; Medeiros M; Monzon JG; Wright GEB; Kollmannsberger CK; Bedard PL; Chen Z; Gelmon KA; McGoldrick N; Kitchlu A; Vijverberg SJH; Masereeuw R; Ross CJD; Liu G; Carleton BC; Maitland-van der Zee AH
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31083486
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
11. Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study.
Shoji S; Hosojima M; Kabasawa H; Kondo R; Miura S; Watanabe S; Aoki N; Kaseda R; Kuwahara S; Tanabe N; Hirayama Y; Narita I; Kikuchi T; Kagamu H; Saito A
BMC Cancer; 2019 Dec; 19(1):1170. PubMed ID: 31791266
[TBL] [Abstract][Full Text] [Related]
12. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
[TBL] [Abstract][Full Text] [Related]
13. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.
Abumiya M; Takahashi N; Takahashi S; Yoshioka T; Kameoka Y; Miura M
Sci Rep; 2021 Mar; 11(1):6362. PubMed ID: 33737618
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
Sai H; Mitsumori M; Yamauchi C; Araki N; Okumura S; Nagata Y; Nishimura Y; Hiraoka M
Int J Clin Oncol; 2004 Jun; 9(3):149-53. PubMed ID: 15221597
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
16. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
[TBL] [Abstract][Full Text] [Related]
17. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
18. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for chronic kidney disease after chemotherapy for testicular cancer.
Inai H; Kawai K; Ikeda A; Ando S; Kimura T; Oikawa T; Onozawa M; Miyazaki J; Uchida K; Nishiyama H
Int J Urol; 2013 Jul; 20(7):716-22. PubMed ID: 23186076
[TBL] [Abstract][Full Text] [Related]
20. Normobaric hyperoxia preconditioning ameliorates cisplatin nephrotoxicity.
Saadat A; Shariat Maghani SS; Rostami Z; Davoudi A; Davoudi F; Shafie A; Eynollahi B
Ren Fail; 2014 Feb; 36(1):5-8. PubMed ID: 24059271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]